Showing 5371-5380 of 9923 results for "".
- Olympian Suni Lee Speaks on AD Panelhttps://practicaldermatology.com/news/olympian-suni-lee-speaks-ad-panel/2467107/Gymnast Suni Lee plans to defend her Olympic gold medal this summer in Paris, but first, she took time to participate in a panel discussion on a topic that has plagued her for several years: atopic dermatitis, or eczema. The 21-year-old American joined National Eczema Association President
- Analysis: Few Dermatologists Share Sun Protection Advice on TikTokhttps://practicaldermatology.com/news/analysis-few-dermatologists-share-sun-protection-advice-tiktok/2467072/A new analysis in the Journal of Drugs in Dermatology shows a significant gap in the presence of board-certified dermatologists (BCDs) on TikTok, particularly concerning sun protection content. "Limited studies have analyzed sources of TikTok videos associated with sun safety and
- Study: Advanced AI Enhances Melanoma Detectionhttps://practicaldermatology.com/news/study-advanced-ai-enhances-melanoma-detection/2467071/A new study suggests a novel deep-learning model based on diagnostic data may help harness the power of neural networks and artificial intelligence (AI) to more accurately diagnose melanoma.
- Survey: 43% With Acne Worry They'll Never Have Clear Skinhttps://practicaldermatology.com/news/survey-43-acne-worry-theyll-never-have-clear-skin/2467063/Ninety percent of acne sufferers experience daily insecurities related to their acne, and 43% worry they will never have clear skin, according to a new survey conducted by Cutera, Inc. June is Acne Awareness Month, and Cutera said in a press release that the findings of the survey “highli
- Neoadjuvant Ipilimumab and Nivolumab Therapy Improves Survival in Stage III Melanomahttps://practicaldermatology.com/news/neoadjuvant-ipilimumab-and-nivolumab-therapy-improves-survival-stage-iii-melanoma/2467064/New phase 3 study results from the NADINA study suggest that neoadjuvant (neoadj) therapy with ipilimumab (IPI) and nivolumab (NIVO) followed by response-driven adjuvant therapy was associated with increased event-free survival (EFS) in patients with macroscopic stage III melanoma. The re
- Study: Upadacitinib Produces Sustained Improvements in 140 Weekshttps://practicaldermatology.com/news/study-upadacitinib-produces-sustained-improvements-140-weeks/2467045/Patients with moderate-to-severe atopic dermatitis (AD) experienced sustained improvements in skin signs/symptoms through 140 weeks while receiving upadacitinib and rates of long-term patient-related outcome improvements were numerically higher with upadacitinib 30 mg compared with upadacitinib 1
- Ruxolitinib cream 1.5% Demonstrates Tolerability, Safety Over 52 Weeks in Childrenhttps://practicaldermatology.com/news/ruxolitinib-cream-15-demonstrates-tolerability-safety-over-52-weeks-children/2467044/Ruxolitinib cream 1.5% demonstrated consistently good tolerability and safety over 52 weeks in children 2 to 11 years old with extensive moderate-to-severe atopic dermatitis (AD) in a study presented this month at the Revolutionizing Atopic Dermatitis (RAD) Conference in Chicago, Illinois.
- FDA Approves Adbry Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)https://practicaldermatology.com/news/fda-approves-adbry-autoinjector-treatment-adults-moderate-severe-atopic-dermatitis-ad/2467043/The FDA has approved LEO Pharma's Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.1 The new autoinjector (300 mg/2 mL) will provide another option for adult patients in addit
- Moderate-to-Severe AA Linked to AD Comorbidityhttps://practicaldermatology.com/news/moderate-severe-aa-linked-ad-comorbidity/2467042/Patients with moderate-to-severe alopecia areata (AA) had higher prevalence and incidence of atopic dermatitis (AD) comorbidity and higher prevalence of moderate-to-severe AD than those with mild AA in a study presented this month at the Revolutionizing Alopecia, Vitligo, and Eczema (RAVE) Confer
- Suntegrity Recalls Multiple Lots of Sunscreen Foundationhttps://practicaldermatology.com/news/suntegrity-recalls-multiple-lots-sunscreen-foundation/2467041/Suntegrity Skincare has announced that it is recalling nine lots of Suntegrity Impeccable Skin Sunscreen Foundation (Multiple Shades) due to the discovery of a higher-than-acceptable microbiological mold count (Aspergillus sydowii), according to an FDA alert. According to the man